Waregem (Belgium) / Rotterdam (The Netherlands)[1], 11 December 2014 – Arseus announces today it will provide an update on the US compounding market, following the media advisory release by Patients and Physicians for Rx Access (http://saverxaccess.org/). The media advisory release states that Catamaran, the nation’s third largest Pharmacy Benefit Manager (PBM), has chosen United Compounding Management (UCM) as its strategic partner in providing coverage for compounded medications in 2015.
Ger van Jeveren (CEO) and Jake Jackson (Member of the Fagron Executive Committee and responsible for Fagron North America) will provide further details today in a conference call. The conference call starts at 17:00 CET. You may join the call from 16:45 CET onwards by calling
+31 (0)10 713 72 95 (the Netherlands) or +32 (0)2 404 03 34 (Belgium).
For further information:
Marieke Palstra
Director Investor Relations
+31 88 33 11 213
marieke.palstra@arseus.com
Arseus profile
Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron’s own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.
The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the links below for the press release and the attachment: